1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Most relevant
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
Delayed Nasdaq Copenhagen  -  05/25 10:17:27 am EDT
77.80 DKK   +3.18%
09:44aViroGates announces the CE-IVD accreditation of its finger-prick blood-testing product, suPARnostic« POC+
AQ
05/10VIROGATES : Healthy growth
AQ
05/04VIROGATES ANNOUNCES ITS INTERIM REPORT FOR Q1, 2022 : Record quarterly revenue and doubling of clinical customers
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about VIROGATES A/S
09:44aViroGates announces the CE-IVD accreditation of its finger-prick blood-testing product,..
AQ
05/10VIROGATES : Healthy growth
AQ
05/04VIROGATES ANNOUNCES ITS INTERIM REPO : Record quarterly revenue and doubling of clinical c..
AQ
05/04ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/03Invitation to ViroGates' Q1 2022 presentation
AQ
04/28Resolutions from the Annual General Meeting of ViroGates A/S
AQ
04/28ViroGates A/S Announces Board Changes
CI
04/19VIROGATES A/S : High blood sugar and suPAR levels independently worsen COVID-19 outcomes
PU
04/18ViroGates announces a current total of 33 clinical routine hospital customers and adjus..
AQ
04/13ViroGates gives notice to convene the Annual General Meeting on 28 April 2022
AQ
04/06ViroGates announces clinical routine use in Portugal
AQ
03/25ViroGates issues warrants to key employees
AQ
03/23VIROGATES ANNOUNCES ITS ANNUAL REPOR : Revenue growth of 43% and strong scientific results
AQ
03/23ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/21Invitation to ViroGates' Full Year 2021 presentation
AQ
03/04ViroGates announces new routine customers in Germany
AQ
03/04ViroGates A/S Announces bestbion dx GmbH as Distribution Partner in Germany
CI
02/17ViroGates announces the CE-IVD accreditation of suPARnostic« ELISA on the Chorus Trio p..
AQ
02/17ViroGates A/S announces successful finalization of the development project with DIESSE ..
CI
02/10ViroGates announces a new routine customer in Finland using suPARnostic« TurbiLatex for..
AQ
02/07VIROGATES A/S : Soluble urokinase receptor and mortality in kidney transplant recipients
PU
02/04VIROGATES A/S : Inflammation, hyperglycemia, and adverse outcomes in individuals with diab..
PU
01/27ViroGates announces a new routine customer in Spain using suPARnostic« TurbiLatex for s..
AQ
01/11NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
2021ViroGates publishes the financial calendar for 2022
AQ
2021ViroGates on positive EMA opinion regarding suPAR-guided anakinra treatment (Video)
AQ
2021ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakin..
AQ
2021ViroGates Announces Positive Opinion from the CHMP of the EMA for suPAR-Guided Anakinra..
CI
2021VIROGATES A/S : SuPAR independently predicts severity and length of hospitalisation in pat..
PU
2021ViroGates announces a development, supply and collaboration agreement with Italy-based ..
AQ
2021FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
2021ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
2021NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
2021Interim Report – Q1-Q3, 2021
PU
2021VIROGATES ANNOUNCES ITS INTERIM REPO : Revenue growth of 66% for the first nine months of ..
AQ
2021ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
2021ViroGates announces a delay in the development and launch of its pipeline product suPAR..
AQ
2021ViroGates A/S Announces Delay in the Development of suPARnostic? POC+
CI
2021Invitation to ViroGates' Q3 2021 presentation
AQ
2021Elevated preoperative suPAR is a strong and independent risk marker for postoperative c..
PU
2021VIROGATES A/S : announces a new hospital as a clinical routine customer in Greece
AQ
2021ViroGates A/S Announces New Hospital as Clinical Routine Customer in Greece
CI
2021VIROGATES A/S : SuPAR is associated with risk for thromboembolic complications and mortali..
PU
2021EVALUATION OF SUPAR LEVELS IN PATIEN : An observational cohort study
PU
2021VIROGATES A/S : SuPAR measured using suPARnostic« TurbiLatex predicts critical illness and..
PU
2021VIROGATES A/S : SAVE-MORE study on the effect of suPARnostic« guided anakinra treatment in..
AQ
2021VIROGATES A/S : notification of transactions by persons discharging managerial responsibil..
AQ
2021SUPAR : An exciting biomarker of systemic chronic inflammation
PU
2021VIROGATES : Eagerly awaiting October
AQ
2021VIROGATES ANNOUNCES ITS HALF-YEAR RE : Increasing clinical revenue and positive topline re..
AQ
2021Virogates A/S Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
2021VIROGATES A/S : SuPAR (cut-off levels ⩽4, 4-6, and ⩾6 ng/mL) predicted the n..
PU
2021VIROGATES A/S : Invitation to ViroGates' Q2 2021 presentation
AQ
2021VIROGATES A/S : SuPAR is a useful biomarker to investigate the link between stressful life..
PU
2021VIROGATES A/S : SuPAR is a valuable tool for predicting the risk of developing severe cons..
PU
2021VIROGATES A/S : notification of transactions by persons discharging managerial responsibil..
AQ
2021VIROGATES A/S : announces CE-IVD approval for suPARnostic« TurbiLatex on the Siemens Healt..
AQ
2021NEW STUDY : suPAR cut-offs for stratification of acute medical patients
PU
2021VIROGATES A/S : General Hospital of Nikaia Agios Panteleimon
PU
2021VIROGATES A/S : ED triage at Sismanoglio General Hospital
PU
2021VIROGATES A/S : announces its first clinical routine customer in Italy
AQ
2021VIROGATES A/S : announces a capital increase in connection with the exercise of warrants
AQ
2021PREPRINT PUBLISHED : suPAR guided early anakinra treatment for COVID-19
PU
2021VIROGATES A/S : reports use of suPAR-guided anakinra treatment improved overall clinical o..
AQ
2021ViroGates A/S and the Hellenic Institute for the Study of Sepsis Announce Positive Top-..
CI
2021VIROGATES ANNOUNCES ITS INTERIM REPO : Increasing clinical sales
AQ
2021ViroGates A/S Reports Earnings Results for the First quarter Ended March 31, 2021
CI
2021ViroGates A/S Provides Revenue Guidance for the Year of 2021
CI
2021VIROGATES A/S : Resolutions from the Annual General Meeting of ViroGates A/S
AQ
2021VIROGATES A/S : gives notice to convene the Annual General Meeting on 27 April 2021
AQ
2021VIROGATES A/S : Our annual report for 2020 has been published
PU
2021VIROGATES ANNOUNCES ITS ANNUAL REPOR : Growing revenue and customer base - a robust platfo..
AQ
2021VIROGATES A/S : announces CE-IVD approval for suPARnostic« TurbiLatex on the Abbott Alinit..
AQ
2021VIROGATES A/S : announces a new clinical routine customer in Greece
AQ
2021ViroGates A/S Announces A New Clinical Routine Customer in Greece
CI
1  2Next
Upcoming event on VIROGATES A/S